Lipocine (NASDAQ:LPCN) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

Lipocine Inc. (NASDAQ:LPCN) crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.30 and traded as high as $2.47. Lipocine shares last traded at $2.38, with a volume of 21,514 shares trading hands.

Wall Street Analysts Forecast Growth

LPCN has been the topic of several recent research reports. Wall Street Zen downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings cut shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. Finally, HC Wainwright restated a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $15.00.

Lipocine Trading Down 3.6%

The company has a market cap of $19.61 million, a PE ratio of -1.27 and a beta of 0.48. The firm’s fifty day moving average is $2.30 and its 200 day moving average is $5.51.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The company had revenue of $0.12 million for the quarter, compared to analyst estimates of $0.16 million. Lipocine had a negative return on equity of 66.70% and a negative net margin of 571.18%. As a group, sell-side analysts anticipate that Lipocine Inc. will post -1.91 EPS for the current fiscal year.

Insider Activity

In related news, Director John W. Higuchi purchased 123,000 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were purchased at an average cost of $2.05 per share, with a total value of $252,150.00. Following the purchase, the director owned 163,797 shares of the company’s stock, valued at $335,783.85. This represents a 301.49% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mahesh V. Patel acquired 25,000 shares of the business’s stock in a transaction on Monday, April 6th. The shares were purchased at an average price of $2.03 per share, with a total value of $50,750.00. Following the completion of the purchase, the chief executive officer owned 160,679 shares in the company, valued at $326,178.37. This represents a 18.43% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have purchased 213,000 shares of company stock valued at $434,600. Insiders own 6.35% of the company’s stock.

Institutional Trading of Lipocine

Large investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in Lipocine in the 4th quarter valued at $85,000. Citadel Advisors LLC purchased a new position in Lipocine in the 3rd quarter valued at $41,000. Dimensional Fund Advisors LP boosted its stake in Lipocine by 57.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock worth $153,000 after purchasing an additional 6,982 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in Lipocine during the 1st quarter worth $185,000. Finally, Renaissance Technologies LLC boosted its stake in Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after purchasing an additional 1,300 shares during the last quarter. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.